Mitokinin CSO Nicholas Hertz, PhD, to present at February 2020 Keystone Symposium titled Brain Therapeutics: Disruptive Technologies and Opportunities
February 7, 2020
Mitokinin CSO Nicholas Hertz, PhD, will be presenting an overview of the Company’s PINK1 program at the Keystone Symposium being held February 17-20, 2020 in Santa Fe, NM.
“The Keystone Symposia are important events for the life sciences field,” said Dr. Hertz. “They allow academic and industry participants to keep their fingers on the pulse of emerging research, and to survey the thinking of their peers as new directions and opportunities emerge. We appreciate having the opportunity to present our research to this audience, and look forward to engaging with thought leaders in the Parkinson’s area and beyond to discuss our path forward.”
The conference program can be found here.
Mitokinin is late-preclinical stage biotechnology company developing PINK1-targeted therapeutics for Parkinson’s disease. By selectively amplifying active-form PINK1 activity, Mitokinin believes it can address the cellular pathologies underlying Parkinson’s disease and ultimately slow or halt the progression of the disease. Learn more at www.mitokinin.com.